• Cancer Secrets – Bonus Clip 4 on Immunotherapy PLUS Interview With Tom Lewis - Available Now Through Wednesday, March 27th at 4:30 pm Pacific Time

    https://terrylclark.substack.com/p/cancer-secrets-bonus-clip-4-on-immunotherapy
    Cancer Secrets – Bonus Clip 4 on Immunotherapy PLUS Interview With Tom Lewis - Available Now Through Wednesday, March 27th at 4:30 pm Pacific Time https://terrylclark.substack.com/p/cancer-secrets-bonus-clip-4-on-immunotherapy
    0 Commentarii 0 Distribuiri 398 Views
  • Making better, ready-made CAR T cells for cancer immunotherapy
    https://medicalxpress.com/news/2022-08-ready-made-car-cells-cancer-immunotherapy.html?utm_source=nwletter&utm_medium=email&utm_campaign=daily-nwletter
    Making better, ready-made CAR T cells for cancer immunotherapy https://medicalxpress.com/news/2022-08-ready-made-car-cells-cancer-immunotherapy.html?utm_source=nwletter&utm_medium=email&utm_campaign=daily-nwletter
    MEDICALXPRESS.COM
    Making better, ready-made CAR T cells for cancer immunotherapy
    In CAR T-cell immunotherapy, T cells from a patient's own blood are engineered to carry so-called chimeric antigen receptors (CAR) that enhance the T cells' ability to attack and kill tumor cells. While CAR-T therapy is a powerful approach for certain leukemias and lymphomas, it's not available for many patients who need it. As described in the August 4 Cell Stem Cell, a technique developed by the lab of George Q. Daley, MD, Ph.D., in the Boston Children's Hospital Stem Cell Program, could make CAR T-cell therapy more widely accessible.
    Like
    1
    0 Commentarii 0 Distribuiri 349 Views
  • https://pubmed.ncbi.nlm.nih.gov/26814441/

    Nanoscale
    . 2016 Feb 14;8(6):3785-95. doi: 10.1039/c5nr09208f. Epub 2016 Jan 27.
    Functionalized graphene oxide serves as a novel vaccine nano-adjuvant for robust stimulation of cellular immunity
    Ligeng Xu 1, Jian Xiang, Ye Liu, Jun Xu, Yinchan Luo, Liangzhu Feng, Zhuang Liu, Rui Peng
    Affiliations collapse
    Affiliation
    1Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-based Functional Materials & Devices, Soochow University, Suzhou, 215123, P.R. China. [email protected] [email protected].
    PMID: 26814441 DOI: 10.1039/c5nr09208f
    Free article
    Abstract
    Benefiting from their unique physicochemical properties, graphene derivatives have attracted great attention in biomedicine. In this study, we carefully engineered graphene oxide (GO) as a vaccine adjuvant for immunotherapy using urease B (Ure B) as the model antigen. Ure B is a specific antigen for Helicobacter pylori, which is a class I carcinogen for gastric cancer. Polyethylene glycol (PEG) and various types of polyethylenimine (PEI) were used as coating polymers. Compared with single-polymer modified GOs (GO-PEG and GO-PEI), certain dual-polymer modified GOs (GO-PEG-PEI) can act as a positive modulator to promote the maturation of dendritic cells (DCs) and enhance their cytokine secretion through the activation of multiple toll-like receptor (TLR) pathways while showing low toxicity. Moreover, this GO-PEG-PEI can serve as an antigen carrier to effectively shuttle antigens into DCs. These two advantages enable GO-PEG-PEI to serve as a novel vaccine adjuvant. In the subsequent in vivo experiments, compared with free Ure B and clinically used aluminum-adjuvant-based vaccine (Alum-Ure B), GO-PEG-PEI-Ure B induces stronger cellular immunity via intradermal administration, suggesting promising applications in cancer immunotherapy. Our work not only presents a novel, highly effective GO-based vaccine nano-adjuvant, but also highlights the critical roles of surface chemistry for the rational design of nano-adjuvants.

    Similar articles
    Alum-functionalized graphene oxide nanocomplexes for effective anticancer vaccination.
    Wang X, Cao F, Yan M, Liu Y, Zhu X, Sun H, Ma G.
    Acta Biomater. 2019 Jan 1;83:390-399. doi: 10.1016/j.actbio.2018.11.023. Epub 2018 Nov 15.
    PMID: 30448435
    Synthesis of polymer-functionalized nanoscale graphene oxide with different surface charge and its cellular uptake, biosafety and immune responses in Raw264.7 macrophages.
    Wang B, Su X, Liang J, Yang L, Hu Q, Shan X, Wan J, Hu Z.
    Mater Sci Eng C Mater Biol Appl. 2018 Sep 1;90:514-522. doi: 10.1016/j.msec.2018.04.096. Epub 2018 May 1.
    PMID: 29853120
    Immunostimulatory oligonucleotides-loaded cationic graphene oxide with photothermally enhanced immunogenicity for photothermal/immune cancer therapy.
    Tao Y, Ju E, Ren J, Qu X.
    Biomaterials. 2014 Dec;35(37):9963-9971. doi: 10.1016/j.biomaterials.2014.08.036. Epub 2014 Sep 15.
    PMID: 25224368
    Recent progress of graphene oxide as a potential vaccine carrier and adjuvant.
    Cao W, He L, Cao W, Huang X, Jia K, Dai J.
    Acta Biomater. 2020 Aug;112:14-28. doi: 10.1016/j.actbio.2020.06.009. Epub 2020 Jun 10.
    PMID: 32531395 Review.
    Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant.
    Hafner AM, Corthésy B, Merkle HP.
    Adv Drug Deliv Rev. 2013 Oct;65(10):1386-99. doi: 10.1016/j.addr.2013.05.013. Epub 2013 Jun 7.
    PMID: 23751781 Review.
    See all similar articles
    Cited by 7 articles
    Intranasal vaccination with influenza HA/GO-PEI nanoparticles provides immune protection against homo- and heterologous strains.
    Dong C, Wang Y, Gonzalez GX, Ma Y, Song Y, Wang S, Kang SM, Compans RW, Wang BZ.
    Proc Natl Acad Sci U S A. 2021 May 11;118(19):e2024998118. doi: 10.1073/pnas.2024998118.
    PMID: 33941704 Free PMC article.
    SPIO Enhance the Cross-Presentation and Migration of DCs and Anionic SPIO Influence the Nanoadjuvant Effects Related to Interleukin-1β.
    Liu H, Dong H, Zhou N, Dong S, Chen L, Zhu Y, Hu HM, Mou Y.
    Nanoscale Res Lett. 2018 Dec 20;13(1):409. doi: 10.1186/s11671-018-2802-0.
    PMID: 30570682 Free PMC article.
    Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune Potentiation.
    Chattopadhyay S, Chen JY, Chen HW, Hu CJ.
    Nanotheranostics. 2017 Jun 9;1(3):244-260. doi: 10.7150/ntno.19796. eCollection 2017.
    PMID: 29071191 Free PMC article. Review.
    Single-cell mass cytometry and transcriptome profiling reveal the impact of graphene on human immune cells.
    Orecchioni M, Bedognetti D, Newman L, Fuoco C, Spada F, Hendrickx W, Marincola FM, Sgarrella F, Rodrigues AF, Ménard-Moyon C, Cesareni G, Kostarelos K, Bianco A, Delogu LG.
    Nat Commun. 2017 Oct 24;8(1):1109. doi: 10.1038/s41467-017-01015-3.
    PMID: 29061960 Free PMC article.
    Graphene and the Immune System: A Romance of Many Dimensions.
    Mukherjee SP, Bottini M, Fadeel B.
    Front Immunol. 2017 Jun 13;8:673. doi: 10.3389/fimmu.2017.00673. eCollection 2017.
    https://pubmed.ncbi.nlm.nih.gov/26814441/ Nanoscale . 2016 Feb 14;8(6):3785-95. doi: 10.1039/c5nr09208f. Epub 2016 Jan 27. Functionalized graphene oxide serves as a novel vaccine nano-adjuvant for robust stimulation of cellular immunity Ligeng Xu 1, Jian Xiang, Ye Liu, Jun Xu, Yinchan Luo, Liangzhu Feng, Zhuang Liu, Rui Peng Affiliations collapse Affiliation 1Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-based Functional Materials & Devices, Soochow University, Suzhou, 215123, P.R. China. [email protected] [email protected]. PMID: 26814441 DOI: 10.1039/c5nr09208f Free article Abstract Benefiting from their unique physicochemical properties, graphene derivatives have attracted great attention in biomedicine. In this study, we carefully engineered graphene oxide (GO) as a vaccine adjuvant for immunotherapy using urease B (Ure B) as the model antigen. Ure B is a specific antigen for Helicobacter pylori, which is a class I carcinogen for gastric cancer. Polyethylene glycol (PEG) and various types of polyethylenimine (PEI) were used as coating polymers. Compared with single-polymer modified GOs (GO-PEG and GO-PEI), certain dual-polymer modified GOs (GO-PEG-PEI) can act as a positive modulator to promote the maturation of dendritic cells (DCs) and enhance their cytokine secretion through the activation of multiple toll-like receptor (TLR) pathways while showing low toxicity. Moreover, this GO-PEG-PEI can serve as an antigen carrier to effectively shuttle antigens into DCs. These two advantages enable GO-PEG-PEI to serve as a novel vaccine adjuvant. In the subsequent in vivo experiments, compared with free Ure B and clinically used aluminum-adjuvant-based vaccine (Alum-Ure B), GO-PEG-PEI-Ure B induces stronger cellular immunity via intradermal administration, suggesting promising applications in cancer immunotherapy. Our work not only presents a novel, highly effective GO-based vaccine nano-adjuvant, but also highlights the critical roles of surface chemistry for the rational design of nano-adjuvants. Similar articles Alum-functionalized graphene oxide nanocomplexes for effective anticancer vaccination. Wang X, Cao F, Yan M, Liu Y, Zhu X, Sun H, Ma G. Acta Biomater. 2019 Jan 1;83:390-399. doi: 10.1016/j.actbio.2018.11.023. Epub 2018 Nov 15. PMID: 30448435 Synthesis of polymer-functionalized nanoscale graphene oxide with different surface charge and its cellular uptake, biosafety and immune responses in Raw264.7 macrophages. Wang B, Su X, Liang J, Yang L, Hu Q, Shan X, Wan J, Hu Z. Mater Sci Eng C Mater Biol Appl. 2018 Sep 1;90:514-522. doi: 10.1016/j.msec.2018.04.096. Epub 2018 May 1. PMID: 29853120 Immunostimulatory oligonucleotides-loaded cationic graphene oxide with photothermally enhanced immunogenicity for photothermal/immune cancer therapy. Tao Y, Ju E, Ren J, Qu X. Biomaterials. 2014 Dec;35(37):9963-9971. doi: 10.1016/j.biomaterials.2014.08.036. Epub 2014 Sep 15. PMID: 25224368 Recent progress of graphene oxide as a potential vaccine carrier and adjuvant. Cao W, He L, Cao W, Huang X, Jia K, Dai J. Acta Biomater. 2020 Aug;112:14-28. doi: 10.1016/j.actbio.2020.06.009. Epub 2020 Jun 10. PMID: 32531395 Review. Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant. Hafner AM, Corthésy B, Merkle HP. Adv Drug Deliv Rev. 2013 Oct;65(10):1386-99. doi: 10.1016/j.addr.2013.05.013. Epub 2013 Jun 7. PMID: 23751781 Review. See all similar articles Cited by 7 articles Intranasal vaccination with influenza HA/GO-PEI nanoparticles provides immune protection against homo- and heterologous strains. Dong C, Wang Y, Gonzalez GX, Ma Y, Song Y, Wang S, Kang SM, Compans RW, Wang BZ. Proc Natl Acad Sci U S A. 2021 May 11;118(19):e2024998118. doi: 10.1073/pnas.2024998118. PMID: 33941704 Free PMC article. SPIO Enhance the Cross-Presentation and Migration of DCs and Anionic SPIO Influence the Nanoadjuvant Effects Related to Interleukin-1β. Liu H, Dong H, Zhou N, Dong S, Chen L, Zhu Y, Hu HM, Mou Y. Nanoscale Res Lett. 2018 Dec 20;13(1):409. doi: 10.1186/s11671-018-2802-0. PMID: 30570682 Free PMC article. Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune Potentiation. Chattopadhyay S, Chen JY, Chen HW, Hu CJ. Nanotheranostics. 2017 Jun 9;1(3):244-260. doi: 10.7150/ntno.19796. eCollection 2017. PMID: 29071191 Free PMC article. Review. Single-cell mass cytometry and transcriptome profiling reveal the impact of graphene on human immune cells. Orecchioni M, Bedognetti D, Newman L, Fuoco C, Spada F, Hendrickx W, Marincola FM, Sgarrella F, Rodrigues AF, Ménard-Moyon C, Cesareni G, Kostarelos K, Bianco A, Delogu LG. Nat Commun. 2017 Oct 24;8(1):1109. doi: 10.1038/s41467-017-01015-3. PMID: 29061960 Free PMC article. Graphene and the Immune System: A Romance of Many Dimensions. Mukherjee SP, Bottini M, Fadeel B. Front Immunol. 2017 Jun 13;8:673. doi: 10.3389/fimmu.2017.00673. eCollection 2017.
    PUBMED.NCBI.NLM.NIH.GOV
    Functionalized graphene oxide serves as a novel vaccine nano-adjuvant for robust stimulation of cellular immunity - PubMed
    Benefiting from their unique physicochemical properties, graphene derivatives have attracted great attention in biomedicine. In this study, we carefully engineered graphene oxide (GO) as a vaccine adjuvant for immunotherapy using urease B (Ure B) as the model antigen. Ure B is a specific antigen for …
    Like
    1
    0 Commentarii 0 Distribuiri 1K Views
  • **Liver Cancer Therapeutics Market to Reach USD 7,382.1 Million by 2027; Rising Cases of Liver Cancer to Fuel Product Demand, states Fortune Business Insights™ **
    The global liver cancer therapeutics market size is expected to reach USD 7,382.1 million by 2027, registering a CAGR of 20.2% during the forecast period. The emergence of effective drugs and therapies for the treatment of liver cancer will subsequently spur lucrative opportunities for the market, states Fortune Business Insights, in a report, titled “Liver Cancer Therapeutics Market Size, Share &COVID-19 Impact Analysis, By Therapy Type (Targeted Drug Therapy, Immunotherapy, and Chemotherapy), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027.” The market size stood at USD 1,730.9 million in 2019.

    Request Sample PDF:

    https://www.fortunebusinessinsights.com/enquiry/sample/liver-cancer-therapeutics-market-104657

    The coronavirus incident has brought the world to an unprecedented stop. We understand that this health crisis has brought an unwonted effect on businesses across various. However, this too, shall pass. Rising support from governments and several companies can help in the fight against this highly infectious virus. There are some industries that are struggling, and some are thriving. More or less, nearly every sector is estimated to be impacted by this pandemic. We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.


    DRIVER RESTRAINTS:

    The Liver Cancer Therapeutics Market report offers an in-depth analysis of the Liver Cancer Therapeutics industry and the demand drivers by highlighting information on several aspects of the market. Prudent Markets addresses all these aspects and provides the latest scoop and detailed eye-opening study on all major & emerging business segments. In addition to this, the report sheds light on the industry developments by key players, which are contributing to the expansion of this industry. The development scope, feasibility study, Liver Cancer Therapeutics market concentration, and maturity analysis is elaborated in this report.

    Information given in the research report pertains to different technological advancements introduced in recent years, which allows for a meticulous analysis of the industry and offers a more comprehensive understanding to the readers.

    The outbreak of covid-19 in the global market has made companies uncertain about their future scenario as the prolonged lock-down finds a serious economic slump. The latest survey on COVID-19 Outbreak-Global Liver Cancer Therapeutics Market is conducted to provide hidden gems performance analysis. Essential growth factors and study of Basis points [BPS] have been discussed in the following report. Research Report explains a detailed overview of market dynamics, segmentation, product portfolio, business plans, and the latest development in the industry.

    The report on the liver cancer therapeutics market, specifically mentions minute and significant improvements in the global market in recent times. The report also offers a wide-ranging study fixated on emerging trends and new innovative products. The robust research methodology involving primary interviews and desk research is covered in the report while also providing a noteworthy overview of the R&D activities and latest developments to support emerging companies to strengthen their position and strategize to remain at the forefront.

    Highlights of the Report:
    1. Market Penetration: Comprehensive information on the product portfolios of the top players in the Supply Chain Analytics market.
    2. Product Development/Innovation: Detailed insights on the upcoming technologies, RandD activities, and product launches in the market
    3. Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market
    4. Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies
    5. Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Supply Chain Analytics market
    **The Report Lists the Key Companies in the Liver Cancer Therapeutics Market:**
    ·
    Bayer HealthCare Pharmaceuticals Inc. (Leverkusen, Germany)
    ·
    Bristol-Myers & Squibb Company (New York, U.S)
    ·
    Pfizer Inc. (New York, U.S)
    ·
    Exelixis, Inc. (California, U.S)
    ·
    Merck Sharp &Dohme Corp. (New jersey, U.S)
    ·
    Eisai Inc. (Tokyo, Japan)
    ·
    Eli Lilly and Company (Indiana, U.S)
    ·
    F. Hoffmann-La Roche Ltd (Basel, Switzerland)
    ·
    Other Players
    **Liver Cancer Therapeutics Market to Reach USD 7,382.1 Million by 2027; Rising Cases of Liver Cancer to Fuel Product Demand, states Fortune Business Insights™ ** The global liver cancer therapeutics market size is expected to reach USD 7,382.1 million by 2027, registering a CAGR of 20.2% during the forecast period. The emergence of effective drugs and therapies for the treatment of liver cancer will subsequently spur lucrative opportunities for the market, states Fortune Business Insights, in a report, titled “Liver Cancer Therapeutics Market Size, Share &COVID-19 Impact Analysis, By Therapy Type (Targeted Drug Therapy, Immunotherapy, and Chemotherapy), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027.” The market size stood at USD 1,730.9 million in 2019. Request Sample PDF: https://www.fortunebusinessinsights.com/enquiry/sample/liver-cancer-therapeutics-market-104657 The coronavirus incident has brought the world to an unprecedented stop. We understand that this health crisis has brought an unwonted effect on businesses across various. However, this too, shall pass. Rising support from governments and several companies can help in the fight against this highly infectious virus. There are some industries that are struggling, and some are thriving. More or less, nearly every sector is estimated to be impacted by this pandemic. We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future. DRIVER RESTRAINTS: The Liver Cancer Therapeutics Market report offers an in-depth analysis of the Liver Cancer Therapeutics industry and the demand drivers by highlighting information on several aspects of the market. Prudent Markets addresses all these aspects and provides the latest scoop and detailed eye-opening study on all major & emerging business segments. In addition to this, the report sheds light on the industry developments by key players, which are contributing to the expansion of this industry. The development scope, feasibility study, Liver Cancer Therapeutics market concentration, and maturity analysis is elaborated in this report. Information given in the research report pertains to different technological advancements introduced in recent years, which allows for a meticulous analysis of the industry and offers a more comprehensive understanding to the readers. The outbreak of covid-19 in the global market has made companies uncertain about their future scenario as the prolonged lock-down finds a serious economic slump. The latest survey on COVID-19 Outbreak-Global Liver Cancer Therapeutics Market is conducted to provide hidden gems performance analysis. Essential growth factors and study of Basis points [BPS] have been discussed in the following report. Research Report explains a detailed overview of market dynamics, segmentation, product portfolio, business plans, and the latest development in the industry. The report on the liver cancer therapeutics market, specifically mentions minute and significant improvements in the global market in recent times. The report also offers a wide-ranging study fixated on emerging trends and new innovative products. The robust research methodology involving primary interviews and desk research is covered in the report while also providing a noteworthy overview of the R&D activities and latest developments to support emerging companies to strengthen their position and strategize to remain at the forefront. Highlights of the Report: 1. Market Penetration: Comprehensive information on the product portfolios of the top players in the Supply Chain Analytics market. 2. Product Development/Innovation: Detailed insights on the upcoming technologies, RandD activities, and product launches in the market 3. Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market 4. Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies 5. Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Supply Chain Analytics market **The Report Lists the Key Companies in the Liver Cancer Therapeutics Market:** · Bayer HealthCare Pharmaceuticals Inc. (Leverkusen, Germany) · Bristol-Myers & Squibb Company (New York, U.S) · Pfizer Inc. (New York, U.S) · Exelixis, Inc. (California, U.S) · Merck Sharp &Dohme Corp. (New jersey, U.S) · Eisai Inc. (Tokyo, Japan) · Eli Lilly and Company (Indiana, U.S) · F. Hoffmann-La Roche Ltd (Basel, Switzerland) · Other Players
    WWW.FORTUNEBUSINESSINSIGHTS.COM
    Request a Sample - Liver Cancer Therapeutics Market Size, Share and Global Industry Trend Forecast till 2025
    The global liver cancer therapeutics market size was USD 1,730.9 million in 2019. The global impact of COVID-19 has been unprecedented and staggering, with liver cancer therapeutics witnessing a positive demand shock across all regions amid the
    0 Commentarii 0 Distribuiri 507 Views
  • The global non-Hodgkin lymphoma treatment market size is projected to reach USD 12.57 billion by the end of 2026. The increasing number of regulatory approvals will aid the growth of the market in the coming years. According to a report published by Fortune Business Insights, titled “Non-Hodgkin Lymphoma Treatment Market Size, Share & Industry Analysis, By Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, and Others), By Disease Type (B-cell Lymphoma, and T-cell Lymphoma), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), and Regional Forecast, 2019-2026,” the market was worth USD 6.60 billion in 2018 and will exhibit a CAGR of 8.4% during the forecast period.

    For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/non-hodgkin-lymphoma-treatment-market-102642
    The global non-Hodgkin lymphoma treatment market size is projected to reach USD 12.57 billion by the end of 2026. The increasing number of regulatory approvals will aid the growth of the market in the coming years. According to a report published by Fortune Business Insights, titled “Non-Hodgkin Lymphoma Treatment Market Size, Share & Industry Analysis, By Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, and Others), By Disease Type (B-cell Lymphoma, and T-cell Lymphoma), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), and Regional Forecast, 2019-2026,” the market was worth USD 6.60 billion in 2018 and will exhibit a CAGR of 8.4% during the forecast period. For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/non-hodgkin-lymphoma-treatment-market-102642
    WWW.FORTUNEBUSINESSINSIGHTS.COM
    Non-Hodgkin Lymphoma Treatment Market Size, Share & Growth, 2026
    The global non-Hodgkin lymphoma treatment market size was valued at USD 6.60 billion in 2018 and is projected to reach USD 12.57 billion by 2026, exhibiting a CAGR of 8.4% during the forecast period.
    0 Commentarii 0 Distribuiri 613 Views
  • Strides Down Different Avenues of Cancer Research with Brendon Coventry.

    Brendon Coventry is an associate professor of surgery in Adelaide, South Australia (The University of Adelaide).

    He's spoken with Richard in previous interviews, and always brings a keen perspective to the latest research. In particular he addresses the "notion of immunotherapy" and the extensive studies trying to pinpoint optimum timing, such as pre-surgical oncology treatment versus post-surgery.


    Listen to it here: https://bit.ly/3yBOK2n


    Episode also available on Apple Podcasts: apple.co/30PvU9C
    .
    .
    .
    .
    #breastcancer #breastcancerawareness #cancer #breastcancersurvivor #cancersucks #cancersurvivor #breastcancerfighter #BreastCancerSupport #breastcancerresearch #breastcancerfight #Findinggeniuspodcast #Healthpodcast #InternalMedicinepodcast #Biosciencespodcast
    Strides Down Different Avenues of Cancer Research with Brendon Coventry. Brendon Coventry is an associate professor of surgery in Adelaide, South Australia (The University of Adelaide). He's spoken with Richard in previous interviews, and always brings a keen perspective to the latest research. In particular he addresses the "notion of immunotherapy" and the extensive studies trying to pinpoint optimum timing, such as pre-surgical oncology treatment versus post-surgery. Listen to it here: https://bit.ly/3yBOK2n Episode also available on Apple Podcasts: apple.co/30PvU9C . . . . #breastcancer #breastcancerawareness #cancer #breastcancersurvivor #cancersucks #cancersurvivor #breastcancerfighter #BreastCancerSupport #breastcancerresearch #breastcancerfight #Findinggeniuspodcast #Healthpodcast #InternalMedicinepodcast #Biosciencespodcast
    Strides Down Different Avenues of Cancer Research with Brendon Coventry
    0 Commentarii 0 Distribuiri 5K Views
  • Therapeutic Vaccination as a Solution to Cancer?

    Brendon Coventry is an associate professor of surgery and medical researcher from Adelaide, South Australia. Splitting his time between the clinic and the lab, Coventry stresses the importance of true translational work, and encourages increased funding for it.

    Listen to it here: https://bit.ly/3sIPcZ8

    Episode also available on Apple Podcasts: http://apple.co/30PvU9C
    .
    .
    .
    .
    #breastcancer #cancer #breastcancersurvivor #cancersucks #cancersurvivor #vaccinetherapy #vaccineforcancer #melanoma #immunotherapy #chemotherapy #surgery #translationalresearch #Findinggeniuspodcast #Healthpodcast #InternalMedicinepodcast #Biosciencespodcast
    Therapeutic Vaccination as a Solution to Cancer? Brendon Coventry is an associate professor of surgery and medical researcher from Adelaide, South Australia. Splitting his time between the clinic and the lab, Coventry stresses the importance of true translational work, and encourages increased funding for it. Listen to it here: https://bit.ly/3sIPcZ8 Episode also available on Apple Podcasts: http://apple.co/30PvU9C . . . . #breastcancer #cancer #breastcancersurvivor #cancersucks #cancersurvivor #vaccinetherapy #vaccineforcancer #melanoma #immunotherapy #chemotherapy #surgery #translationalresearch #Findinggeniuspodcast #Healthpodcast #InternalMedicinepodcast #Biosciencespodcast
    Therapeutic Vaccination as a Solution to Cancer?
    0 Commentarii 0 Distribuiri 2K Views
  • https://www.timesofisrael.com/new-israeli-drug-cured-moderate-to-serious-covid-cases-within-days-hospital/?fbclid=IwAR1xDSMlcVTJnpQb4pbZ263dP9Y83XJ7Uc9khWGA0Sqj-04-zJCNflNPlhY
    Medicine developed at Ichilov moderates immune response, helps prevent deadly cytokine storm, researchers say; 29 of 30 phase 1
    trial patients left hospital within 3-5 days. All 30 patients recovered.
    It uses exosomes — tiny carrier sacs that shuttle materials between cells — to deliver a protein called CD24 to the lungs, which
    Arber has spent decades researching.
    https://www.cancer.gov/news-events/cancer-currents-blog/2019/cd24-immunotherapy-target
    https://www.timesofisrael.com/new-israeli-drug-cured-moderate-to-serious-covid-cases-within-days-hospital/?fbclid=IwAR1xDSMlcVTJnpQb4pbZ263dP9Y83XJ7Uc9khWGA0Sqj-04-zJCNflNPlhY Medicine developed at Ichilov moderates immune response, helps prevent deadly cytokine storm, researchers say; 29 of 30 phase 1 trial patients left hospital within 3-5 days. All 30 patients recovered. It uses exosomes — tiny carrier sacs that shuttle materials between cells — to deliver a protein called CD24 to the lungs, which Arber has spent decades researching. https://www.cancer.gov/news-events/cancer-currents-blog/2019/cd24-immunotherapy-target
    WWW.TIMESOFISRAEL.COM
    New Israeli drug cured 29 of 30 moderate/serious COVID cases in days — hospital
    Medicine developed at Ichilov moderates immune response, helps prevent deadly cytokine storm, researchers say; 29 of 30 phase 1 trial patients left hospital within 3-5 days
    0 Commentarii 0 Distribuiri 533 Views
  • The Zoomed-Out Therapeutic Picture of Cancer with a Clinician-Researcher

    Dr. Doru Paul is Associate Professor of Clinical Medicine at Weill Cornell Medicine, a practicing oncologist and hematologist who has treated more than 10,000 patients with various types of cancers over the years, and a clinical and translational researcher who has been involved with over 30 studies in oncology.

    Listen to it here: https://bit.ly/306FEKT

    Episode also available on Apple Podcasts: http://apple.co/30PvU9C
    .
    .
    .
    .
    #cancersurvivor #cancer #immunotherapy #FDGPET #chemotherapy #chemo #headcancers #neckcancers #monoclonalantibodies #Findinggeniuspodcast #Healthpodcast #InternalMedicinepodcast #Biosciencespodcast
    The Zoomed-Out Therapeutic Picture of Cancer with a Clinician-Researcher Dr. Doru Paul is Associate Professor of Clinical Medicine at Weill Cornell Medicine, a practicing oncologist and hematologist who has treated more than 10,000 patients with various types of cancers over the years, and a clinical and translational researcher who has been involved with over 30 studies in oncology. Listen to it here: https://bit.ly/306FEKT Episode also available on Apple Podcasts: http://apple.co/30PvU9C . . . . #cancersurvivor #cancer #immunotherapy #FDGPET #chemotherapy #chemo #headcancers #neckcancers #monoclonalantibodies #Findinggeniuspodcast #Healthpodcast #InternalMedicinepodcast #Biosciencespodcast
    The Zoomed-Out Therapeutic Picture of Cancer with Clinician-Researcher Dr. Doru Paul
    0 Commentarii 0 Distribuiri 2K Views
  • Could Immunostimulants Signal the End of Untreatable Tumor Metastasis?

    At Dartmouth College, Steven Fiering is a professor of microbiology, immunology, and genetics, with a primary focus on immunotherapy for cancer.

    While there are good treatments for cancers that have not metastasized, like surgery and radiation, outcomes for metastatic solid tumors are almost universally poor. According to Fiering and many others, immunotherapy might be the solution.

    Listen to it here: https://bit.ly/3q3C6Uc

    Episode also available on Apple Podcasts: apple.co/30PvU9C
    '
    '
    '
    '
    #cancer #cancersucks #cancersurvivor #cancerawareness #cancerprevention #cancertreatment #immunesystem #health #immunesupport #immunebooster #immunity #immunehealth
    Could Immunostimulants Signal the End of Untreatable Tumor Metastasis? At Dartmouth College, Steven Fiering is a professor of microbiology, immunology, and genetics, with a primary focus on immunotherapy for cancer. While there are good treatments for cancers that have not metastasized, like surgery and radiation, outcomes for metastatic solid tumors are almost universally poor. According to Fiering and many others, immunotherapy might be the solution. Listen to it here: https://bit.ly/3q3C6Uc Episode also available on Apple Podcasts: apple.co/30PvU9C ' ' ' ' #cancer #cancersucks #cancersurvivor #cancerawareness #cancerprevention #cancertreatment #immunesystem #health #immunesupport #immunebooster #immunity #immunehealth
    Could Immunostimulants Signal the End of Untreatable Tumor Metastasis?
    0 Commentarii 0 Distribuiri 2K Views
Sponsorizeaza Paginile
Sponsor

We are 100% funded for October.

Thanks to everyone who helped out. 🥰

Xephula monthly operating expenses for 2024 - Server: $143/month - Backup Software: $6/month - Object Storage: $6/month - SMTP Service: $10/month - Stripe Processing Fees: ~$10/month - Total: $175/month

Xephula Funding Meter

Please Donate Here